Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Aldoxorubicin HCl

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CytRx, Nantcell Strike Licensing Agreement for Aldoxorubicin
    CytRx, Nantcell Strike Licensing Agreement for Aldoxorubicin

    31 Jul 2017

    // DDDMAG

    https://www.dddmag.com/news/2017/07/cytrx-nantcell-strike-licensing-agreement-aldoxorubicin

    DDDMAG
    31 Jul 2017
    Share Share
    Soon-Shiong’s NantCell in $356M deal for underperforming CytRx cancer drug
    Soon-Shiong’s NantCell in $356M deal for underperforming CytRx cancer drug

    28 Jul 2017

    // Ben Adams FIERCE BIOTECH

    http://www.fiercebiotech.com/biotech/soon-shiong-s-nantcell-356m-deal-for-underperforming-cytrx-cancer-drug?utm_source=internal&utm_medium=rss

    Ben Adams FIERCE BIOTECH
    28 Jul 2017
    Share Share
    CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up
    CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up

    20 Apr 2017

    // NASDAQ

    http://www.nasdaq.com/article/cytrx-gets-clarity-from-fda-for-aldoxorubicin-nda-shares-up-cm776780

    NASDAQ
    20 Apr 2017
    Share Share
    BRIEF-Cytrx says FDA agreement on regulatory pathway for Aldoxorubicin
    BRIEF-Cytrx says FDA agreement on regulatory pathway for Aldoxorubicin

    19 Apr 2017

    // REUTERS

    http://in.reuters.com/article/brief-cytrx-says-fda-agreement-on-regula-idINASA09J5R

    REUTERS
    19 Apr 2017
    Share Share
    CytRx Plans to File NDA for Once-Failed Sarcoma Drug
    CytRx Plans to File NDA for Once-Failed Sarcoma Drug

    30 Nov 2016

    // Alex Keown BIOSPACE

    http://www.biospace.com/News/cytrx-plans-to-file-nda-for-once-failed-sarcoma/440456/source=TopBreaking?intcid=homepage-seekernewssection-tabtopbreakingnews

    Alex Keown BIOSPACE
    30 Nov 2016
    Share Share